Legal & General Group Plc Has $14.35 Million Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Legal & General Group Plc boosted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 20.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 836,850 shares of the biotechnology company's stock after buying an additional 139,840 shares during the quarter. Legal & General Group Plc owned approximately 0.35% of ADMA Biologics worth $14,352,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after purchasing an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in ADMA Biologics by 1.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after buying an additional 700 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in ADMA Biologics by 2.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock valued at $614,000 after purchasing an additional 751 shares in the last quarter. Maryland State Retirement & Pension System raised its position in shares of ADMA Biologics by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock valued at $1,365,000 after buying an additional 897 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 967 shares during the period. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 0.9 %

Shares of NASDAQ:ADMA traded down $0.19 during midday trading on Monday, hitting $21.13. 275,843 shares of the stock were exchanged, compared to its average volume of 3,603,972. The business's 50-day moving average price is $18.26 and its 200 day moving average price is $18.21. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 12 month low of $6.19 and a 12 month high of $23.64. The stock has a market capitalization of $4.99 billion, a price-to-earnings ratio of 75.46 and a beta of 0.53.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.